Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06779773 · ClinicalTrials.gov registry record
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
A clinical trial of Geographic Atrophy and Macular Degeneration, sponsored by Astellas Pharma Global Development.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT06779773 is a study of Geographic Atrophy and Macular Degeneration that is actively recruiting participants, run by Astellas Pharma Global Development. The registered enrollment target is 1,000 participants, above the 185-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (441% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06779773, a study of Geographic Atrophy and Macular Degeneration, is actively recruiting participants, sponsored by Astellas Pharma Global Development.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.
Conditions Studied
Interventions
- DRUG Avacincaptad pegol (ACP)
Study Locations (20)
Florida
- Florida Eye Clinic - Altamonte Springs
- Advanced Retina Institute - Bonita Springs
- University of Miami - Coral Gables
- Retina Care Specialists - Palm Beach Gardens
- Eye Physicians of Pinellas PA dba Eye Institute of West Florida - Tampa
- Retina Specialists of Tampa - Wesley Chapel
California
- The Retina Partners - Encino
- Harvard Eye Associates - Laguna Hills
- Retina Consultants of Southern CA - Redlands
- Retinal Consultants Medical Group Inc - Sacramento
- Retina Macula Institute - Torrance
Arizona
- Phoenix Retina Clinical Trials, LLC - Phoenix
- Retinal Consultants of AZ - Phoenix
- Retina Macula Institute of Arizona - Scottsdale
Colorado
- Rocky Mountain Lions Eye Institute - Aurora
- Retina Consultants of Southern Colorado - Colorado Springs
- Colorado Retina Associates, PLLC - Lakewood
Connecticut
- Coastal Eye Surgeons - Greenwich
Georgia
- Southeast Retina Center, P.C. - Augusta
Illinois
- University Retina and Macula Associates, P.C. - Oak Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2030-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06779773
The ClinicalTrials.gov registry entry for NCT06779773 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 185-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (441% higher). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Avacincaptad pegol (ACP) is the first listed.
NCT06779773 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06779773 about?
NCT06779773 is a clinical study titled "A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy". This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form ...
What is the current status of trial NCT06779773?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-01-22. Estimated completion is 2030-01-31.
What conditions does trial NCT06779773 study?
This clinical trial studies the following conditions: Geographic Atrophy, Macular Degeneration.
What interventions are being tested in trial NCT06779773?
The interventions under investigation include: Avacincaptad pegol (ACP) (DRUG).
Who is sponsoring clinical trial NCT06779773?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06779773 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.